Skip to main content

Table 4 Characteristics of the YOFMF, AOFMF, and LOFMF patients in a sensitivity analysis removing patients with mutations in exon 10 or overlapping rheumatic diseases (univariate analyses)

From: Musculoskeletal manifestations occur predominantly in patients with later-onset familial Mediterranean fever: Data from a multicenter, prospective national cohort study in Japan

Variable YOFMF (n = 91) AOFMF (n = 74) LOFMF (n = 61) p value
YOFMF vs AOFMF vs LOFMF YOFMF vs others Others vs LOFMF
Typical FMF 33/91 (36%) 25/74 (34%) 25/61 (41%) 0.68 1.00 0.44
Family history 15/91 (16%) 9/74 (12%) 6/61 (10%) 0.47 0.32 0.51
Exon 1 mutations (+) 11/91 (12%) 6/74 (8%) 0/61 (0%) 0.021 0.041 0.0078
Exon 2 mutations (+) 62/91 (68%) 58/74 (78%) 40/61 (66%) 0.20 0.55 0.32
Exon 3 mutations (+) 22/91 (24%) 14/74 (19%) 12/61 (20%) 0.67 0.41 0.86
More than two MEFV mutations (+) 48/91 (53%) 39/74 (53%) 24/61 (39%) 0.20 0.42 0.10
Thoracic pain 17/91 (19%) 19/74 (26%) 17/61 (28%) 0.36 0.20 0.38
Abdominal pain 55/91 (60%) 34/74 (46%) 13/61 (21%) < 0.0001 0.0002 < 0.0001
Arthritis 40/91 (44%) 39/74 (53%) 39/61 (64%) 0.053 0.043 0.036
Myalgia 4/76 (5%) 12/56 (21%) 12/42 (29%) 0.0018 0.0007 0.016
  1. Number (percentage) presented. p values established using Fisher’s exact test or Mann–Whitney U test
  2. YOFMF young-onset FMF, AOFMF adult-onset FMF, LOFMF late-onset FMF, FMF familial Mediterranean fever, MEFV Mediterranean fever gene